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IMPORTANCE The natural history and themanagement of patients with asymptomatic aortic
stenosis (AS) have not been fully examined in the current era.
OBJECTIVE To determine the clinical outcomes of patients with asymptomatic AS using data
from the Heart Valve Clinic International Database.
DESIGN, SETTING, AND PARTICIPANTS This registry was assembled bymerging data from
prospectively gathered institutional databases from 10 heart valve clinics in Europe, Canada,
and the United States. Asymptomatic patients with an aortic valve area of 1.5 cm2 or less and
preserved left ventricular ejection fraction (LVEF) greater than 50% at entry were considered
for the present analysis. Data were collected from January 2001 to December 2014, and data
were analyzed from January 2017 to July 2018.
MAIN OUTCOMES ANDMEASURES Natural history, need for aortic valve replacement (AVR),
and survival of asymptomatic patients with moderate or severe AS at entry followed up in a
heart valve clinic. Indications for AVRwere based on current guideline recommendations.
RESULTS Of the 1375 patients included in this analysis, 834 (60.7%) weremale, and themean
(SD) age was 71 (13) years. A total of 861 patients (62.6%) had severe AS (aortic valve area
less than 1.0 cm2). Themean (SD) overall survival during medical management (mean [SD]
follow up, 27 [24] months) was 93% (1%), 86% (2%), and 75% (4%) at 2, 4, and 8 years,
respectively. A total of 104 patients (7.6%) died under observation, including 57 patients
(54.8%) from cardiovascular causes. The crude rate of sudden death was 0.65% over the
duration of the study. A total of 542 patients (39.4%) underwent AVR, including 388 patients
(71.6%) with severe AS at study entry and 154 (28.4%) with moderate AS at entry who
progressed to severe AS. Those with severe AS at entry who underwent AVR did so at a mean
(SD) of 14.4 (16.6) months and amedian of 8.7 months. Themean (SD) 2-year and 4-year
AVR-free survival rates for asymptomatic patients with severe AS at baseline were 54% (2%)
and 32% (3%), respectively. In those undergoing AVR, the 30-day postprocedural mortality
was 0.9%. In patients with severe AS at entry, peak aortic jet velocity (greater than 5m/s) and
LVEF (less than 60%) were associated with all-cause and cardiovascular mortality without
AVR; these factors were also associated with postprocedural mortality in those patients with
severe AS at baseline who underwent AVR (surgical AVR in 310 patients; transcatheter AVR in
78 patients).
CONCLUSIONS AND RELEVANCE In patients with asymptomatic AS followed up in heart valve
centers, the risk of sudden death is low, and rates of overall survival are similar to those
reported from previous series. Patients with severe AS at baseline and peak aortic jet velocity
of 5.0m/s or greater or LVEF less than 60% have increased risks of all-cause and
cardiovascular mortality even after AVR. The potential benefit of early intervention should be
considered in these high-risk patients.
JAMA Cardiol. 2018;3(11):1060-1068. doi:10.1001/jamacardio.2018.3152
Published online October 3, 2018.
Editor's Note page 1068
Supplemental content
CMEQuiz at
jamanetwork.com/learning
and CMEQuestions
page 1135
Author Affiliations:Author
affiliations are listed at the end of this
article.
Corresponding Author: Patrizio
Lancellotti, MD, PhD, GIGA
Cardiovascular Sciences,
Departments of Cardiology, Heart
Valve Clinic, University of Liège
Hospital, Centre Hospitalier
Universitaire du Sart Tilman, Avenue
de L’Hòpital 1, 4000 Liège, Belgium
(plancellotti@chu.ulg.ac.be).
Research
JAMACardiology | Original Investigation
1060 (Reprinted) jamacardiology.com
© 2018 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Walaeus Library LUMC User  on 09/26/2019
I n thewesternworld, calcific aortic stenosis (AS), themostcommonvalvular heart disease, represents amajor publichealthburden.1Currently, there isnopharmacological treat-
ment that prevents or slows the progression of AS.2 Surgical
aortic valve replacement (SAVR)and transcatheter aortic valve
replacement (TAVR) are theonly therapies to significantly im-
prove both survival and symptoms3,4 and are recommended
in symptomatic patients with severe AS.5,6 Themanagement
of patients with asymptomatic severe AS, particularly the
choice between early intervention vs watchful waiting, con-
tinues to be a matter of debate.7,8 Current guidelines advo-
cate delayingAVRuntil symptomsor left ventricular (LV) sys-
tolic dysfunction develop.5,6 However, observational studies
in 20109 and 201510 have suggested that early elective AVR
might improve outcomes in patients with severe asymptom-
atic AS. This approach has been reinforced by continued ad-
vances in surgical techniques and aortic valve prostheses, the
advent of TAVR, and the lowperioperativemortality andmor-
bidity rates achieved in valve centers of reference.11,12 How-
ever, preemptive surgery before onset of symptomsor LV sys-
tolic dysfunction is considered in only a selected group of
patients after careful risk stratification. This is at least in part
because the evidence for intervention in asymptomatic se-
vere AS is derived from small, heterogeneous, retrospective,
single-center studies,whichhavegenerally included theneed
for AVR (not always motivated by the development of symp-
tomsorLVdysfunction) in the composite studyendpoint.13-20
Moreover, decision making for AVR remains particularly dif-
ficult in older patients in whom it is sometimes unclear if the
benefits of intervention outweigh the risk.5,6
In recent years, the establishment of multidisciplinary
services delivered by experts in valvular heart disease has
become the basis for the implementation of heart valve
clinics.21 These clinics provide standardized care based on
international evidence-based norms and facilitate large clini-
cal registries, which may be used to further refine guideline
recommendations and quality improvement. The Heart
Valve Clinic International Database (HAVEC) is a multicenter
registry created for prospective data collection of patients
with echocardiographic confirmation of AS and other valve
diseases.22 The objective of the present study was to deter-
mine the natural history and outcomes of patients with
moderate or severe AS who are followed up in a heart valve
clinic.
Methods
The data, analytic methods, and study materials can be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure after approval
of the HAVEC group. Data are centrally collected at the
Department of Cardiology, Centre Hospitalier Universitaire
du Sart Tilman, Liège, Belgium. This retrospective analysis
of clinically acquired data was approved by the respective
institutional review boards of each participating center, and
informed consent was waived because collected data were
deidentified and retrospective.
Study Population
TheHAVEC registrywas assembledbymergingdata frompro-
spectively gathered electronic institutional databases of
10 heart valve clinics, as defined by the European Society of
Cardiology Working Group in Valvular Heart Diseases,13
collected between 2001 and 2014. The analyses were then
performed retrospectively. Patients were eligible for this reg-
istry if they had AS diagnosed with the use of 2-dimension
echocardiographyat 1of theparticipatingcenters andwere fol-
lowed-up according to available guidelines on a regular basis.
Exclusioncriteria includedaortic valvearea (AVA)greater than
1.5 cm2; class I indications for AVR (rest AS–related or exer-
cise AS–related symptoms [ie, angina, syncope, and dysp-
nea] or LV ejection fraction [EF] less than 50%); concomitant
congenital heart valve disease more than mild mitral, tricus-
pid,orpulmonicvalvedisease;orpriorvalvesurgery.Thestudy
was conducted in accordance with the respective institu-
tional guidelines, national legal requirements, and the re-
vised Helsinki declaration.23
Doppler Echocardiography
Transthoracic echocardiographywasperformedaspart of rou-
tineclinicalpracticeusingcommerciallyavailablesystems.The
severity of ASwas evaluated according to standardmethods.
Peak aortic jet velocity was derived from transaortic flow, re-
corded with continuous wave Doppler using a multiwindow
approach. Peak andmeangradientswere calculatedusing the
simplified Bernoulli equation. The continuity equation was
used to calculate AVA. Moderate and severe AS were defined
as an AVA between 1.0 and 1.5 cm2 and less than 1.0 cm2, re-
spectively. Left ventricular EFwas estimated by the Simpson
biplane method.
Follow-up
Follow-upwas organizedwithin each participating center ac-
cording to available guidelines (every 6-12months in patients
with severe AS) (eTable 1 in Supplement 1). Data collection
started after baseline evaluationuntil last available contact or
death. Follow-up data were obtained by direct patient inter-
view and clinical examination; telephone calls with physi-
cians, patients, ornextof kin; or reviewof autopsy recordsand
Key Points
Question What is the outcome of patients with asymptomatic
aortic stenosis (AS) followed up in a specialized heart valve clinic?
Findings In this study using data from the Heart Valve Clinic
International Database including 1375 patients from 10 heart valve
clinics, left ventricular ejection fraction less than 60% and peak
aortic jet velocity greater than 5m/s were independent factors
associated with all-cause and cardiovascular mortality in patients
with asymptomatic severe AS. The adverse association of these
factors with survival remains significant following aortic valve
replacement, suggesting the need for earlier intervention.
Meaning Taking into consideration the low procedural risk
associated with aortic valve replacement, the potential benefit of
earlier intervention should be considered in high-risk patients with
asymptomatic severe AS.
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death certificates. Informationwas collected regardingdevel-
opmentof cardiac symptoms, subsequentAVR (performed for
development of guideline indications: symptom onset, ab-
normal exercise test, peak aortic velocity greater than5.5m/s,
or rapidprogressionofASseverity), anddeath.24Exercise test-
ing was performed in selected patients (572 of 1375 patients
[41.6%]), especially when the symptomatic status was un-
clear. Cardiac deaths were classified as directly related to AS
(ie, sudden death or heart failure) or to other cardiac pathol-
ogy (ie, fatal myocardial infarction). All-cause mortality was
theprimaryendpointof thestudy;cardiovascular-relatedmor-
tality was the secondary end point. Follow-up echocardiog-
raphy data were obtained in all patients who underwent AVR
to confirm the progression of moderate to severe AS (ie, AVA
less than 1 cm2).
Statistical Analysis
Data are reported asmeanswith standard deviations for con-
tinuous variables or numbers and percentages of individuals
for categorical variables. Group comparisons for categorical
variables were obtained with χ2 test and for continuous vari-
ables with Mann-Whitney U test if the normality of data was
violated based on a Shapiro-Wilk test. Analyses of overall and
cardiovascularmortalitywereperformedby censoringdata at
the time of AVR. Multivariable analysis was then performed
by including covariates selected on the basis of their known
link to outcome in patients with AS (ie, age, sex, comorbidi-
ties, AS severity, and LVEF) into a Cox proportional hazard
model. Peak aortic jet velocity (greater than or equal to 5m/s)
and LVEF (less than 60%) were also expressed as categorical
variables.6,25 Survival curves were computed based on the
Kaplan-Meiermethod.Regardingthepredictionofall-causeand
cardiovascular death, receiver operating characteristic curve
analyses were performed, and areas under the curve (AUCs)
were reported. Themost accurate cutoff values (ie, best com-
promise between sensitivity and specificity) were obtained
usingYouden index.APvalue less than .05wasconsideredsta-
tistically significant, and all P values were 2-tailed. Statistical
analyses were performed using SPSS version 23 (IBM).
Results
A total of 1763 patients were included in the present registry,
of whom 388 (22.0%)were excluded because ofmissing data
regarding LVEF or AS severity. The characteristics of the re-
maining 1375 patients who fulfilled inclusion criteria are de-
scribed in Table 1. The mean (SD; range) AVA was 0.94 (0.3;
0.30-1.50) cm2 andwas less than 1 cm2 in861patients (62.6%)
(Table 1).
Table 1. Comparison of PatientsWithModerate vs Severe Aortic Stenosis (AS) at Baseline
Variable
Mean (SD)
P Value
All
(N = 1375)
Moderate AS
(n = 514)
Severe AS
(n = 861)
Age, y 71 (13) 68 (13) 72 (12) <.001
Male, No. (%) 834 (60.7) 337 (65.6) 497 (57.7) .004
Height, cm 167 (9) 168 (9) 166 (9) .04
Weight, kg 75 (15) 78 (15) 73 (16) <.001
Body surface area, m2 1.8 (0.2) 1.9 (0.2) 1.8 (0.2) <.001
Systolic blood pressure, mm Hg 140 (19) 140 (18) 140 (20) .97
Diastolic blood pressure, mm Hg 78 (11) 78 (10) 77 (11) .41
Hypertension, No. (%) 833 (60.6) 327 (63.6) 506 (58.8) .07
Diabetes, No. (%) 245 (17.8) 95 (18.4) 150 (17.4) .74
Smoker, No. (%) 415 (30.1) 180 (35.0) 235 (27.3) .002
Dyslipidemia, No. (%) 722 (52.5) 299 (58.1) 423 (49.1) <.001
Chronic obstructive pulmonary
disease, No. (%)
104 (7.6) 48 (9.3) 56 (6.5) .03
β-Blockers, No. (%) 482 (35.1) 150 (29.2) 332 (38.6) <.001
Angiotensin-converting enzyme
inhibitor, No. (%)
447 (32.5) 177 (34.4) 270 (31.4) .31
LV mass, g/m2 207 (73) 209 (58) 206 (81) .51
LVESV, mL 39 (21) 40 (22) 39 (20) .53
LVEDV, mL 103 (34) 110 (35) 100 (33) <.001
SV index, mL/m2 44 (11) 46 (11) 42 (11) <.001
LV ejection fraction, % 65.5 (7.4) 66 (6.9) 65 (7.3) .003
Peak aortic velocity, m/s 3.8 (0.8) 3.3 (0.7) 4.1 (0.7) <.001
Mean aortic pressure gradient,
mm Hg
37 (17) 26 (12) 44 (16) <.001
Aortic valve area, cm2 0.94 (0.3) 1.20 (0.2) 0.78 (0.1) <.001
Mitral E wave velocity, cm/s 87 (28) 84 (22) 88 (31) .02
Mitral E/A ratio 1 (0.6) 1 (0.4) 1 (0.6) .80
E/e’ ratio 10.8 (5.7) 10.6 (4.6) 10.9 (6.4) .28
Abbreviations: EDV, end-diastolic
volume; ESV, end-systolic volume;
LV, left ventricular; SV, stroke volume.
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OutcomeDuringMedical Management
Clinical follow-up information for patients in the 10 centers is
shown ineTable 1 inSupplement 1. Echocardiographicdata re-
garding the rate of progression of initiallymoderate to severe
ASwerenot routinely available, although severeASwasdocu-
mented in all patients with moderate AS at baseline who
underwent AVR during follow-up. The mean (SD; range)
follow-up time was 27 (24; 2-224) months. A total of 542 pa-
tients (39.4%) required AVR (SAVR, 429 [79.2%]; TAVR, 113
[20.8%]). The 2-year, 4-year, and 8-year overall survival rates
for the entire cohort during medical management were 93%
(1%), 86% (2%), and 75% (4%), respectively. The cardiovascu-
lardeath–free survival rateswere96%(1%)at2years,90%(1%)
at 4 years, and 83% (3%) at 8 years. Of the 104 deaths during
medicalmanagement, 57 (54.8%)were froma cardiovascular
cause, including 38 fromheart failure and 7 from sudden car-
diac death. The incidence rate of sudden death was 2.5 cases
per 1000 patient-years.
PatientsWith Severe AS at Entry
Among the 861 patients with severe AS at entry, the 2-year,
4-year, and 8-year overall survival rates were 92% (1%), 80%
(3%), and 65% (8%), respectively (Figure 1A); the cardiovas-
cular death–free survival rates at 2 years, 4 years, and 8 years
were 96% (1%), 87% (3%), and 71% (9%), respectively
(Figure 1B); and the 2-year, 4-year, and 8-year AVR-free sur-
vival rates were 54% (2%), 32% (3%), and 12% (3%), respec-
tively (Figure 1C). Of the 64 deaths during medical manage-
ment in patients with severe AS, 32 (50%) were from a
cardiovascular cause, including 23 from heart failure, 4 from
sudden cardiac death, 2 from myocardial infarction, 2 from
stroke, and 1 from pulmonary embolism.
Aortic valve replacementwas performed in 388of 861 pa-
tients with severe AS (45.1%), with SAVR performed in 310
(79.9%) (Table 2). Indications for AVRwere development of a
class I indication in 366 patients (94.3%), a class IIa indica-
tion in 18 (4.6%), anda class IIb indication in4 (1.0%). In these
patients, themean (SD) time between inclusion and AVRwas
14.4 (16.6) months, and the median (range) time was 8.7
(0-133) months. Combined coronary artery revascularization
was performed in 82 patients (26.5%) at the time of SAVR.
PatientsWithModerate AS at Entry
Among the 514 patients with moderate AS at baseline, 154
(30.0%) underwent AVR (SAVR, 110 [71.4%]; TAVR, 44
[28.6%]); 128 patients (83.1%) developed class I indications,
22 (14.3%) developed class IIa indications, and 4 (2.6%)
developed class IIb indications. Echocardiography preceding
AVR confirmed that the stenosis had progressed to the severe
stage (AVA less than 1.0 cm2) in all patients. Combined coro-
nary artery revascularization was performed in 34 patients at
the time of AVR. The mean (SD) time between inclusion and
AVR was 29.9 (24.4) months, and the median (range) time
was 22.6 (0-98) months. The mean (SD) overall survival rate
was 94% (1%) at 2 years, 89% (2%) at 4 years, and 78% (4%) at
8 years follow-up (eFigure 1 in Supplement 1). In these
patients with moderate AS at baseline, AVR-free survival
rates are provided in eFigure 2 in Supplement 1. Of the 40
deaths during medical management, 25 were cardiovascular
in nature, including heart failure in 14 and sudden death in 3.
Of note, 2 of 3 patients who died suddenly had confirmed
severe AS on echocardiography.
Predictors of Outcome
For the entire cohort, age, dyslipidemia, chronic obstructive
pulmonary disease, higher systolic blood pressure, peak aor-
tic jet velocity, and LVEFwere associatedwith all-causemor-
Figure 1. Kaplan-Meier Estimates for Events in Patients
With Severe Aortic Stenosis (AS)
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Kaplan-Meier analyses of overall survival (A), cardiovascular death–free survival
(B), and aortic valve replacement (AVR)–free survival (C) for patients with
severe AS at entry to the registry.
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tality. Age, peak aortic jet velocity, and LVEF were also asso-
ciated with cardiovascular death (eTable 2 in Supplement 1).
Inpatientswith severeAS (Table3), echocardiographicde-
terminants of all-cause mortality identified in the multivari-
able analysis were peak aortic jet velocity greater than 5 m/s
and LVEF. Independent determinants of cardiovascular mor-
tality were age, diabetes, peak aortic jet velocity greater than
5m/s, andLVEF.Whenpeak aortic jet velocity andLVEFwere
taken as continuous variables, both were independently as-
sociated with cardiovascular mortality (Table 3). Using re-
Table 3. Multivariable Predictors ofMortality (Aortic Valve Replacement Censored)With Echocardiographic
Data as Continuous and Categorical Variables in PatientsWith Severe Aortic Stenosis at Baseline
Predictor
All-Cause Mortality Cardiovascular Mortality
HR (95% CI) P Value HR (95% CI) P Value
Continuous Variables
Age, per 1 y 1.05 (1.02-1.08) .002 1.05 (1.00-1.10) .03
Systolic blood pressure, per mm Hg 1.02 (1.01-1.03) .004 NA NA
Diabetes 1.34 (0.73-2.44) .35 2.84 (1.24-6.55) .01
Dyslipidemia 0.65 (0.38-1.12) .12 NA NA
Chronic obstructive pulmonary disease 2.47 (1.14-5.34) .02 NA NA
Peak aortic velocity, per 0.1 m/s 1.03 (0.99-1.07) .11 1.01 (1.03-1.14) .001
LVEF, per 1% 0.90 (0.86-0.94) <.001 0.90 (0.85-0.96) .002
Categorical Variables
Age, per 1 y 1.05 (1.02-1.09) .001 1.06 (1.01-1.11) .02
Systolic blood pressure, per mm Hg 1.02 (1.01-1.03) .003 NA NA
Diabetes 1.38 (0.76-2.50) .29 2.95 (1.26-6.90) .01
Dyslipidemia 0.58 (0.34-1.00) .051 NA NA
Chronic obstructive pulmonary disease 2.56 (1.19-5.48) .02 NA NA
Peak aortic velocity ≥5 m/s 2.05 (1.01-4.16) .046 6.31 (2.51-15.9) <.001
LVEF <60% 5.01 (2.93-8.57) <.001 4.47 (2.06-9.70) <.001
Abbreviations: HR, hazard ratio;
LVEF, left ventricular ejection
fraction; NA, not applicable.
Table 2. Comparison of Survivors vs Nonsurvivors in PatientsWith Severe Aortic Stenosis at Baseline
Variable
Mean (SD)
P Value
Survivor
(n = 738)
Death Under
Medical Treatment
(n = 64)
Death After AVR
(n = 59)
Age, y 72 (12) 78 (7)a 72 (10)b <.001
Male, No. (%) 425 (57.6) 37 (58) 35 (59) .97
Height, cm 166 (9) 167 (10) 169 (8) .11
Weight, kg 73 (16) 73 (15) 73 (12) .94
Body surface area, m2 1.81 (0.2) 1.81 (0.2) 1.82 (0.2) .84
Systolic blood pressure, mm Hg 139 (19) 149 (23)a 142 (19) .001
Diastolic blood pressure, mm Hg 77 (11) 80 (10) 78 (11) .12
Hypertension, No. (%) 436 (59.1) 43 (67) 27 (46) .04
Diabetes, No. (%) 119 (16.1) 17 (27) 14 (24) .06
Smoker, No. (%) 194 (26.3) 24 (37) 17 (29) .18
Dyslipidemia, No. (%) 381 (51.6) 27 (42) 15 (25) <.001
Chronic obstructive pulmonary
disease, No. (%)
42 (5.7) 9 (14) 5 (9) .03
β-Blockers, No. (%) 282 (38.2) 26 (41) 24 (41) .94
Angiotensin-converting enzyme
inhibitor, No. (%)
225 (30.5) 25 (39) 20 (34) .39
LV mass, g/m2 202 (83) 227 (67) 218 (67) .06
LVESV, mL 39 (21) 39 (14) 40 (16) .96
LVEDV, mL 101 (34) 95 (27) 102 (29) .49
SV index, mL/m2 42 (11) 41 (11) 42 (11) .72
LV ejection fraction, % 66 (7) 60 (5)a 64 (9)b <.001
Peak aortic velocity, m/s 4.1 (0.7) 4.2 (0.9) 4.4 (0.8)a .001
Mean aortic pressure gradient,
mm Hg
43 (16) 42 (17) 49 (18)a,b .02
Aortic valve area, cm2 0.78 (0.15) 0.77 (0.15) 0.77 (0.16) .72
Abbreviations: AVR, aortic valve
replacement; EDV, end-diastolic
volume; ESV, end-systolic volume;
LV, left ventricular; SV, stroke volume.
a Significant difference with
survivors.
b Significant difference with death
under medical treatment.
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ceiver operating characteristic curve analysis, the best cutoff
values regarding the prediction of overall death were 59.6%
for LVEF (AUC,0.73; sensitivity, 81%; specificity, 56%) and4.7
m/s for peak aortic jet velocity (AUC, 0.50; sensitivity, 30%;
specificity, 80%). The AUCs for LVEF and peak aortic jet ve-
locity were 0.68 and 0.59, respectively, for the prediction of
cardiovascular death. Of note, therewas a graded association
of reduced survivalwith increasedpeak aortic jet velocity and
with decreased LVEF (Figure 2). No EF threshold higher than
65% further affected survival. For peak aortic jet velocity, no
additional prognostic information was obtained for veloci-
ties between 4 and 5m/s. Similar data were obtained for AVA
(eTable 3 andeFigure 3 inSupplement 1) for both total andcar-
diovascular mortality. In patients with initially moderate AS,
the best cutoffs associated with the outcomes were 64% for
LVEF and 3.0 m/s for peak aortic jet velocity (eTable 4 in
Supplement 1).
Post-AVROutcomes
Thirty-daymortality followingAVRwasvery low(n = 13 [0.9%];
SAVR, 7; TAVR,6).During follow-up, a total of 69patientswho
underwentAVRdied (SAVR, 49; TAVR, 20), including 22 from
acardiovascular cause, ofwhich 17were fromheart failure and
2were from sudden death. Themean (SD) 2-year, 4-year, and
6-year postprocedural overall survival rates were 83% (2%),
75% (4%), and68%(6%), respectively. Patientswith severeAS
at baseline andpeak aortic velocity greater than5m/shad sig-
nificantly lower mean (SD) postoperative survival rates than
those with peak aortic velocity less than 5 m/s (2 years: 73%
[8%] vs 84% [2%]; 4 years: 65% [10%] vs 78% [4%]; 6 years:
54% [13%] vs 70% [6%]; P = .03). Similarly, patients with se-
vereASatentrywith reducedbaselineLVEF less than60%also
had lower mean (SD) postoperative survival rates than those
withbaselineLVEFof60%orgreater (2years:67%[7%]vs87%
[5%];4years: 63%[8%]vs78%[4%];6years: 63%[8%]vs69%
[7%];P = .02). Inmultivariableanalysis, age (hazard ratio [HR],
1.03; 95% CI, 1.01-1.06; P = .003), diabetes (HR, 2.62; 95% CI,
1.90-4.95; P = .003), dyslipidemia (HR, 0.2; 95% CI, 0.10-
0.37;P < .001), andpeakaortic velocitygreater than5m/s (HR,
2.20; 95% CI, 1.16-4.18; P = .02) were independently associ-
atedwithpostoperative survival. Of note, LVEF less than60%
was not associated with reduced postoperative survival in
multivariable analysis.
Discussion
Themanagement of patients with asymptomatic AS has con-
tinued to challenge clinicians.6,21 A randomized clinical trial
(Evaluation of Transcatheter Aortic Valve Replacement Com-
pared to Surveillance for PatientsWith Asymptomatic Severe
Aortic Stenosis; NCT03042104) has been initiated to com-
pare outcomes of asymptomatic patients with severe ASwho
are randomized to transfemoral TAVRvs clinical andechocar-
diographic follow-up (ie, active surveillance). To our knowl-
edge, a randomized surgical trial hasnot beenperformed, and
current practice patterns vary widely. In the present registry,
forpatientswithasymptomaticmoderateor severeASandpre-
servedLVEFgreater than50%atbaseline followedup inheart
valve clinics over the intermediate term, themean 2-year and
4-year overall survival ratesundermedicalmanagementwere
93%and86%,respectively.Thecruderateofsuddendeathover
the follow-up interval was low (0.65%) and represented ap-
proximately one-tenth of all cardiovascular deaths.
InpatientswithsevereASatentry, age, systolicbloodpres-
sure level, comorbidities (eg, chronic obstructive pulmonary
disease), peak aortic jet velocity greater than 5m/s, and LVEF
less than 60%were associated with all-cause mortality. Age,
Figure 2. Kaplan-Meier Estimates for Events in PatientsWith Severe Aortic Stenosis According to Left Ventricular Ejection Fraction (LVEF)
and Peak Aortic Jet Velocity
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Kaplan-Meier analyses of overall survival in patients with severe aortic stenosis at baseline as a function of peak aortic jet velocity (A) and LVEF (B).
a Significant difference with peak aortic jet velocity of 5 m/s or greater.
b Significant difference with LVEF less than 60%.
c Significant difference with LVEF of 60% to 65%.
Outcomes of Patients With Asymptomatic Aortic Stenosis Followed Up in Heart Valve Clinics Original Investigation Research
jamacardiology.com (Reprinted) JAMA Cardiology November 2018 Volume 3, Number 11 1065
© 2018 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Walaeus Library LUMC User  on 09/26/2019
peak aortic jet velocity of 5m/s or greater, and LVEF less than
60%were also independently associatedwith cardiovascular
death.
During follow-up, 34% of patients required AVR, and this
rate rose to 59% at 4 years. Most AVRswere dictated by a class
I indication (ie, symptom development), and most cardiovas-
cular deaths were related to heart failure. The 30-day mortal-
ity followingAVR in this serieswasvery low (0.9%).AfterAVR,
the negative effect of peak aortic jet velocity remained signifi-
cant, while LVEF less than 60%was no longer associatedwith
cardiovascular death. Interestingly, in patients withmoderate
AS at entry who progressed to severe AS andwere referred for
AVR, thebaselinevariablespredictingworseoutcomesweredi-
rectionally similar (peak aortic jet velocity of 3.0m/s or greater
and LVEF less than 60%). Two of 3 patients withmoderate AS
at entry who had sudden cardiac death during follow-up had
confirmed severe AS on surveillance echocardiography.
Approximately one-half of patients diagnosedwithmod-
erate or severe AS do not report symptoms.8,15 The clinically
silent phase of severe AS is associated with a risk of sudden
death ranging from0.25%to1.7%peryear.18,19,25Giventhecur-
rent low periprocedural mortality rates for SAVR and trans-
femoral TAVR, earlier intervention has been advocated, and
toourknowledge, the current strategyofwatchfulwaitinghas
not been examined in a large cohort of patients with asymp-
tomaticmoderate or severeASmonitored in specializedheart
valve clinics. Delay in reporting symptoms is common in pa-
tients with AS.12 Considering an annual mortality rate of ap-
proximately 30% for patients with severe AS, once symp-
toms develop, early recognition of symptoms and timely
referral to intervention are critical.3,4 It has been shown that
when patients are regularly followed up within a heart valve
clinic program, symptomsare recognizedat anearlier and less
severe stage, thus optimizing timing of AVR.12,26 Compared
with previous studies, the low rate of sudden death, the good
overall midterm survival rates, and the very low rate of 30-
day mortality following AVR observed in the HAVEC registry
likely reflect appropriate monitoring, planning, and high ad-
herence toguidelines.13-18However,ourdatahighlight theneed
for additional efforts with probably closer follow-up in these
patients, since the occurrence of overt heart failure remains a
significant problem even in heart valve centers of excellence.
Comorbidities are frequent in elderly individualswithAS,
and AS increases the mortality from myocardial infarction,
stroke, trauma, or emergency noncardiac surgery.27-31 The
HAVEC registrydatahighlighted that age andchronic obstruc-
tive pulmonary disease significantly worsen patients’ prog-
nosis. Age has not been consistently reported as an outcome
predictor in the literature. However, many older adults with
severe AS are not candidates for surgical AVR because of high
surgical risk, advanced age, frailty, or comorbid conditions.32
Some complications after transcatheter AVR (eg, vascular in-
juries) are more common in very elderly patients.3,4
Although supportive data are limited, an LVEF less than
50% is considered the appropriate threshold for defining LV
systolic dysfunction in AS.5,6,33 In the HAVEC registry, pa-
tients with EF between 50% and 59% had less favorable out-
comesandexperiencedmoreheart failure–relateddeaths than
those with EF greater than 60%. These data reinforce obser-
vations from previous retrospective studies33,34 and provide
support for adjusting the cutoff for LVEF (less than 60% in-
steadof less than50%) todefinedysfunctionandconsiderAVR
in asymptomatic severe AS.
Despite limitedevidencewithaclass IIa indication,asymp-
tomatic patients with very severe AS (peak aortic jet velocity
greater than 5 to 5.5m/s) are often referred for AVR.5,6,14 Peak
aortic jet velocity is recordeddirectlywith theuse of continu-
ous Doppler interrogation and, unlike AVA, does not require
calculations and has high reproducibility. Peak aortic jet ve-
locity is a robust prognostic parameter in AS, with increas-
ingly worse outcome from patients with mild to very severe
(greater than 5m/s) stenosis.14,15,19 This gradual effect of ste-
nosis severity was challenged in a 2015 large multicenter ret-
rospective Japanese study.10However, themain limitationsof
this study were the inclusion of patients with LVEF less than
50% and the absence of standardized follow-up and treat-
ment strategy.By contrast, theHAVEC registry confirmedpre-
vious observations regarding stenosis severity in a very large
population of patients with asymptomatic AS evaluated and
monitored in heart valve clinics. In fact, very severe obstruc-
tion (peak aortic jet velocity of 5 m/s or greater) was predic-
tive of all-cause mortality and cardiovascular death regard-
less of treatment strategy in asymptomatic patientswithAS.14
Although AVA encompassed a broad range of values from0.3
to 1.50 cm2, it was also associatedwith outcomes in these pa-
tients (eFigure 3 in Supplement 1). An AVA less than 0.8 cm2
was associated withmarkedly increased risk of all-cause and
cardiovascular mortality.
Limitations
Our study had limitations. Data from a centralized database
(clinical and echocardiographic data at baseline and clinical
data at follow-up) were obtained from each center. However,
because of incomplete echocardiographic data at baseline
and/or during follow-up, a total of 22% of the initially in-
cluded patients were not included in the final study analysis.
Follow-upechocardiographicdatawere also collected fromall
patientswhounderwentAVR to confirm theprogression from
moderate to severe AS (ie, AVA greater than 1 cm2). However,
in the context of this study,wedidnot collect the echocardio-
graphic parameters of AS severity and LV function at
follow-upvisits. This precluded the analysis of the rate of pro-
gression frommoderate to severe AS. Although exercise test-
ing was commonly performed (572 patients), some patients
were considered asymptomatic based solely on question-
naire on symptom status (not available in all centers). The as-
sessment of myocardial strain, which could identify patients
with subclinical LVdysfunction,20wasnot systematicallyper-
formed.The reasons forwhich symptomatic patients diedun-
der medical management could not be ascertained.
Conclusions
This study shows that asymptomatic patients with severe AS
followed up in heart valve clinics have a low risk of sudden
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death and good midterm survival. Asymptomatic patients
with very severe AS (peak aortic jet velocity of 5 m/s or
greater) or with LVEF less than 60% have higher all-cause
and cardiovascular mortality even after successful AVR.
These findings provide support for consideration of early
elective AVR in these patients. Closer and more frequent
(every 6 to 12 months) clinical and echocardiographic
follow-up might be implemented in patients with moderate
AS and a peak aortic jet velocity of 3.0 m/s or greater or LVEF
less than 60%.
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Editor's Note
Thresholds for Valve Replacement in Asymptomatic Patients
With Aortic Stenosis
Patrick T. O’Gara, MD; Robert O. Bonow, MD
The evaluation and treatment of patientswith valvular heart
disease (VHD) have evolved considerably over the past
decade in direct relation to an enhanced understanding of
natural history, refinements in multimodality imaging, im-
provements in surgical tech-
niquesandoutcomes,andthe
transformative emergence of
transcathetervalve replacementand repair. Collectively, these
changes haveprompted valve intervention at earlier stages in
the natural history of heart valve disease. Rapid advances in
the fieldhavepromotedupdates toclinicalpracticeguidelines1
and thedevelopmentofVHDcenters of excellence that canof-
fer patients the full spectrum of services.2 The definition of
suchcenters remainsamatterofdebate, although there is gen-
eral consensus that transparently reported, risk-adjusted,high-
quality, patient-centered outcomes should compose the core
metric by which their value is judged.
In this issue of JAMA Cardiology, Lancellotti et al3 report
the outcomes of 1375 asymptomatic patients with moderate
or severe aortic stenosis (AS) followed up prospectively be-
tween 2001 and 2014 across 10 heart valve clinics with dem-
onstrated interest and expertise in caring for patients with
VHD.3 Traditionally, asymptomatic patients have been man-
aged conservatively, with referral for aortic valve replace-
ment (AVR) based on symptomonset or the demonstration of
a left ventricular ejection fraction less than 50%, although in-
tervention in low surgical risk patients is also felt reasonable
in the presence of very severe AS, rapidly progressive AS, or
an abnormal response to exercise.1 The findings from this in-
ternational patient database generally confirm the low inci-
dence of sudden cardiac death among asymptomatic pa-
tients with AS and recapitulate the observations made in
previously reported natural history studies. However, of im-
portance are the observations that among asymptomatic pa-
tientswith severeAS, a baselinepeak jet velocity at least 5m/s
or an left ventricular ejection fraction less than 60% was as-
sociated with an increased risk of all-cause and cardiovascu-
lar mortality even following AVR. If validated in other stud-
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